Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

NCT ID: NCT06577532

Last Updated: 2025-05-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-24
• Study Completion Date: 2027-08-31

Brief Summary

The purpose of this study is to evaluate the safety, immunogenicity, pharmacodynamics, as well as preliminary efficacy of KRAS neoantigen mRNA vaccine (ABO2102) alone and in combination with toripalimab (anti-PD-1 monoclonal antibody) among participants with KRAS-mutated advanced pancreatic cancer and other solid tumors. The trial includes dose escalation (Part I) and dose expansion(Part II) parts.

Conditions

Pancreatic Neoplasms; Other Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ABO2102

Prat I: Monotherapy

Group Type: EXPERIMENTAL

ABO2102

Intervention Type: DRUG

mRNA encoding mutant KRAS neoantigens, administrated intramuscularly

ABO2102 and Toripalimab

Part I\&II: ABO2102 in combination with Toripalimab

Group Type: EXPERIMENTAL

ABO2102

Intervention Type: DRUG

mRNA encoding mutant KRAS neoantigens, administrated intramuscularly

Toripalimab

Intervention Type: DRUG

Anti-PD-1 antibody, administered intravenously

Interventions

ABO2102

mRNA encoding mutant KRAS neoantigens, administrated intramuscularly

Intervention Type: DRUG

Toripalimab

Anti-PD-1 antibody, administered intravenously

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ≥18 years of age at time of informed consent.

2. Participants with histologically and/ or cytologically confirmed advanced solid tumors (such as pancreatic ductal adenocarcinoma, non-small cell lung cancer, etc.), whose disease has progressed or being intolerant to relevant treatments during or following at least one line of systemic treatment; patients in the second stage include those who have experienced disease progression or intolerance to previous systemic treatments, as well as those who have not received systemic therapy but are deemed by the investigator to potentially benefit from the study treatment based on a comprehensive clinical assessment.

3. Harboring at least one of the targeted KRAS mutants.

4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0~2.

5. Life expectancy of ≥12 weeks.

6. Sufficient organ function.

Exclusion Criteria

1. Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that have been cured, superficial bladder cancer, or carcinoma in situ of the breast or cervix.

2. Received KRAS cancer vaccine before.

3. Immunosuppressants or other immunomodulatory drugs were required within 4 weeks before the first dose of study treatment. Physiological doses of systemic steroids or topical medications are allowed. Topical medications should not exceed the dose recommended in the package insert or have any systemic exposure signs; Or patients with other acquired or congenital immunodeficiency diseases, or a history of organ transplantation who need to use immunosuppressants or other immunomodulatory drugs.

4. History of severe allergies or known allergies to any active or inactive component of the study drug(s).

5. Uncontrolled systemic infection; active tuberculosis.

6. Severe cardiovascular diseases.

7. Has known symptomatic, untreated central nervous system metastases, or CNS metastases requiring continued treatment. Participants with asymptomatic brain metastases and who do not require treatment are eligible for enrolment.

8. Have active autoimmune and inflammatory diseases.

9. Have immediate hypersensitivity, a history of eczema or asthma uncontrolled by topical corticosteroids.

10. Have other serious medical conditions

11. A history of organ transplantation, bone marrow transplantation or hematopoietic stem cell transplantation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Suzhou Abogen Biosciences Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Baiyong Shen

Role: PRINCIPAL_INVESTIGATOR

Ruijin Hospital

Locations

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Xinjing Wang

Role: CONTACT

newvista89@163.com

18817821319

Facility Contacts

Baiyong Shen

Role: primary

Other Identifiers

ABO2102-001

Identifier Type: -

Identifier Source: org_study_id